PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5650.01%
Negative EBIT growth while CRON.TO is at 35.95%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-5650.01%
Negative operating income growth while CRON.TO is at 11.40%. Joel Greenblatt would press for urgent turnaround measures.
-40472.45%
Negative net income growth while CRON.TO stands at 18.08%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-3050.00%
Negative EPS growth while CRON.TO is at 17.83%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-3050.00%
Negative diluted EPS growth while CRON.TO is at 17.83%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
1209.23%
Slight or no buybacks while CRON.TO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
1209.23%
Slight or no buyback while CRON.TO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-33934.54%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-40083.77%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-51.16%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-51.16%
Negative 5Y OCF/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-51.16%
Negative 3Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-117.44%
Negative 10Y net income/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-117.44%
Negative 5Y net income/share CAGR while CRON.TO is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-117.44%
Negative 3Y CAGR while CRON.TO is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
74.46%
Equity/share CAGR of 74.46% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
74.46%
Equity/share CAGR of 74.46% while CRON.TO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
74.46%
Equity/share CAGR of 74.46% while CRON.TO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
110905.89%
Our AR growth while CRON.TO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
No Data
No Data available this quarter, please select a different quarter.
7369.40%
Positive asset growth while CRON.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
552.07%
Positive BV/share change while CRON.TO is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
41942.29%
We expand SG&A while CRON.TO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.